| Catalog No. | DB185018 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 0.156 μg/ml |
|---|
| Range | 0.31-5 μg/mL |
|---|
| Accession |
P20138 |
| Applications |
ELISA |
| Detection method |
Colorimetric |
| Assay type |
Quantitative |
| Recovery |
80-120% |
| Shipping |
2-8 ℃ |
| Stability and Storage |
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Specifications |
Lintuzumab
|
| Alternate Names | 225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, 166089-32-3 |
|---|
| Background | Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225Ac]Ac-lintuzumab clinical trials were discussed in detail in reference. An initial phase I dose-escalation trial demonstrated that for a single infusion of [225Ac]Ac-lintuzumab in patients with relapsed or refractory acute myeloid leukemia, the maximum tolerated dose (MTD) was determined to be 111 kBq/kg with antileukemic activity across all dose levels. No evidence of radiation-induced nephrotoxicity was seen. Peripheral blasts were eliminated in 63% of the patients at doses of >37 kBq/kg. Bone marrow blast reduction was observed in 67% of patients. Subsequently, a multicenter phase I dose-escalation trial was conducted to define MTD, toxicity, and response rate of fractionated-dose [225Ac]Ac-lintuzumab when combined with low-dose cytarabine (LDAC) in older patients with untreated AML who were not candidates for intensive chemotherapy. |
|---|
| Note |
For Research Use Only. |
